Cue Biopharma (CUE) Depreciation & Amortization (CF) (2017 - 2025)

Cue Biopharma has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $678000.0 for Q4 2025.

• Depreciation & Amortization (CF) for Q4 2025 came in at $678000.0, up 591.84% year-over-year; the trailing twelve-month figure through Dec 2025 was $958000.0 (up 141.31% YoY), and the FY2025 annual result was $958000.0, up 141.31% from the prior year.
• Depreciation & Amortization (CF) came in at $678000.0 for Q4 2025 at Cue Biopharma, up from $80000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $678000.0 in Q4 2025 to a low of $80000.0 in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $156500.0 (2023), against an average of $204533.1.
• Across the five-year window, Depreciation & Amortization (CF) slumped 44.33% in 2023 and jumped 591.84% in 2025, its largest moves.
• Cue Biopharma's Depreciation & Amortization (CF) stood at $309662.0 in 2021, then tumbled by 34.44% to $203000.0 in 2022, then plunged by 44.33% to $113000.0 in 2023, then fell by 13.27% to $98000.0 in 2024, then surged by 591.84% to $678000.0 in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $678000.0 (Q4 2025), $80000.0 (Q3 2025), and $99000.0 (Q2 2025), per Business Quant data.